Scarica l'app Stockscreener
1.80
8.16%
-0.16
Dopo l'orario di chiusura:
1.90
0.10
+5.56%
Precedente Chiudi:
$1.96
Aprire:
$1.9
Volume 24 ore:
1.19M
Relative Volume:
1.51
Capitalizzazione di mercato:
$133.29M
Reddito:
$6.96M
Utile/perdita netta:
$-46.51M
Rapporto P/E:
-10.49
EPS:
-0.1716
Flusso di cassa netto:
$-37.99M
1 W Prestazione:
-18.18%
1M Prestazione:
-23.40%
6M Prestazione:
-86.52%
1 anno Prestazione:
-87.32%
Intervallo 1D:
$1.785
$1.91
Intervallo di 1 settimana:
$1.785
$2.205
Portata 52W:
$1.785
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
Nome
Perspective Therapeutics Inc
Settore
Industria
Telefono
509-375-1202
Indirizzo
350 Hills Street, Suite 106, Richland
Confronta CATX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
1.80 | 133.29M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
124.44 | 215.82B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
345.80 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
BSX
Boston Scientific Corp
|
89.70 | 132.67B | 16.75B | 1.85B | 2.37B | 1.25 |
|
MDT
Medtronic Plc
|
82.88 | 106.28B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.36 | 40.63B | 5.72B | 4.17B | 259.90M | 6.97 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-01 | Iniziato | Wedbush | Outperform |
| 2024-09-25 | Iniziato | Truist | Buy |
| 2024-07-25 | Iniziato | BofA Securities | Buy |
| 2024-05-09 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
CATX stock touches 52-week low at $1.87 amid market challenges By Investing.com - Investing.com South Africa
CATX stock touches 52-week low at $1.87 amid market challenges - Investing.com UK
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Analysts - Defense World
What is HC Wainwright’s Estimate for CATX Q2 Earnings? - Defense World
Pheochromocytoma Treatment Market Size in 7MM is expected - openPR.com
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Yahoo Finance
Perspective Therapeutics director Robert Williamson buys $132,151 in stock - Investing.com Australia
Perspective therapeutics CEO Johan Spoor buys $59,672 in stock - Investing.com India
Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock - Investing.com Australia
Perspective Therapeutics director Lori Woods acquires $49,999 in stock By Investing.com - Investing.com Canada
Perspective Therapeutics director Robert Williamson buys $132,151 in stock By Investing.com - Investing.com South Africa
Perspective Therapeutics director Lori Woods acquires $49,999 in stock - Investing.com
Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock By Investing.com - Investing.com UK
Perspective Therapeutics (NYSE:CATX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures - GlobeNewswire Inc.
Perspective Therapeutics (NYSE:CATX) Given “Buy” Rating at HC Wainwright - Defense World
Perspective Therapeutics to Participate in Upcoming April Investor Conferences - The Manila Times
Cancer Treatment Innovator Perspective Therapeutics Lines Up Major April Investor Events - Stock Titan
Swiss National Bank Has $275,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
CATX Q1 EPS Forecast Lowered by Brookline Capital Management - Defense World
Research Analysts Issue Forecasts for CATX Q1 Earnings - Defense World
HighTower Advisors LLC Has $568,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Charles Schwab Investment Management Inc. Sells 26,556 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Royal Bank of Canada Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - Defense World
Bank of New York Mellon Corp Grows Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail
RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk - Marketscreener.com
Perspective Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com Canada
Perspective Therapeutics Reports 2024 Earnings and Clinical Progress - TipRanks
Perspective Therapeutics Inc (CATX) Reports Annual EPS Loss of $1.23, Revenue at $1.5 Million, Surpassing Estimates - GuruFocus.com
Perspective Therapeutics: Expect To Have Sufficient Funding Into Late 2026 - Marketscreener.com
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results - The Manila Times
Perspective Therapeutics Secures 2-Year Runway with $227M Cash, Advances Cancer Trials - Stock Titan
CATX stock touches 52-week low at $2.31 amid market fluctuations - Investing.com
What is HC Wainwright’s Forecast for CATX FY2025 Earnings? - Defense World
Brachytherapy Market Expected to Reach USD 1.5 Billion by 2031 | - openPR
HC Wainwright Reiterates “Buy” Rating for Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics (CATX) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Perspective Therapeutics’ (CATX) Outperform Rating Reaffirmed at Wedbush - Defense World
Perspective Flat on New Drug Trials - Baystreet.ca
Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy - Marketscreener.com
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times
Perspective Therapeutics Announces First Patient Dosed With VMT01 In Combination With Nivolumab In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - Marketscreener.com
Perspective Therapeutics, Inc. Initiates First Patient Dosing in Phase 1/2a Trial of [212Pb]VMT01 for Melanoma Treatment - Nasdaq
Breakthrough Melanoma Treatment: New Alpha Therapy Combined With Opdivo Shows Promise - Stock Titan
Bicara Therapeutics Inc (BCAX): A New Perspective - Stocks Register
Analysts Issue Forecasts for CATX Q4 Earnings - Defense World
HC Wainwright Initiates Coverage on Perspective Therapeutics (NYSE:CATX) - Defense World
Dyne Therapeutics Inc (DYN): A New Perspective - Stocks Register
Brookline Capital Management Estimates CATX FY2024 Earnings - The AM Reporter
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga
Perspective Therapeutics Inc Azioni (CATX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
7.46%
Capitalizzazione:
|
Volume (24 ore):